Anzeige
Mehr »
Samstag, 04.04.2026 - Börsentäglich über 12.000 News
Strategisches Metall: China verknappt Germanium - und diese Aktie könnte davon erheblich profitieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DoWhy is Nebius Group stock climbing today?
DoWhy is CoreWeave stock gaining today?
DoBeyond Meat stock price target lowered to $1 by BMO on weak sales
DoLeerink raises Adagene stock price target to $8 on combination data
DoJefferies reiterates Beyond Inc stock rating on acquisition news
DoBofA reiterates Buy on Beta Technologies stock after FAA win
DoRaymond James cuts Lumexa Imaging stock price target on soft outlook
DoUnion Pacific secures job guarantees in sixth union merger deal
DoNFI Group names Rob Marion president of Motor Coach Industries
DoCerrado Gold Q4 2025 slides: record EBITDA amid transition year
DoLucid updates 2027 Gravity SUV lineup with new standard features
DoStewart acquires Nationwide Appraisal Network to expand valuation services
DoHeritage Global hires Elise DiBenedetto as business development head
DoRuanyun Edai opens Saudi Arabia hub, projects 10% revenue growth
DoCanaccord lowers AngioDynamics stock price target on EBITDA guidance
DoOpenAI buys TBPN to boost AI conversation and communications
DoTruist cuts Tesla stock price target to $400 on weak deliveries
DoBed Bath & Beyond to expand Elfa storage brand globally
DoUK to auction £4bn of Treasury gilts maturing in 2033
DoNordstrom revenue reaches pre-pandemic levels after buyout
DoEvercore ISI reiterates Karman stock rating after filing delay
DoBarclays raises Atlas Energy Solutions stock price target on power deal
DoMorgan Stanley reiterates Ultragenyx stock rating on FDA filing progress
DoCindrigo delays biomass plant start, secures £400,000 loan facility
DoTruist reiterates Hold on Immunovant stock after trial failure